

07-28-05

escc

EXPRESS MAIL LABEL NO.EV 687 633 022 US

**PETITION FOR CERTIFICATE OF  
CORRECTION**

Address to:  
Mail Stop DAC  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attorney Docket	BEAR-006CIP
First Named Inventor	KUMAGAI, YOSHINARI
Patent Number	6,911,425
Issue Date	June 28, 2005
Application Number	09/812,485
Filing Date	March 19, 2001
Title: <i>"INTEGRIN BINDING MOTIF CONTAINING PEPTIDES AND METHODS OF TREATING SKELETAL DISEASES"</i>	


Sir:

Transmitted herewith for filing is a Certificate of Correction for the above-identified patent. Please delete the phrase “[a therapeutically effective amount of]” from claims 1-4. Enclosed is a copy of the Examiner’s Amendment included with the Notice of Allowability which makes the requested deletion of the phrase “a therapeutically effective amount of.”

It is believed that no fee is due since the error was made by the Patent and Trademark Office. However, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. § 1.20, which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 order number BEAR-006CIP.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

By: \_\_\_\_\_

  
Karl Bozicevic  
Registration No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Fax: (650) 327-3231

**Certificate  
AUG 01 2005  
of Correction**

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

PATENT NO : 6,911,425

DATED : June 28, 2005

INVENTOR(S) : KUMAGAI, YOSHINARI, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In col. 41, claim 1, line 3, please delete "[a therapeutically effective amount of]";

In col. 41, claim 2, line 3, please delete "[a therapeutically effective amount of]";

In col. 42, claim 3, line 3, please delete "[a therapeutically effective amount of]";

In col. 42, claim 4, line 3, please delete "[a therapeutically effective amount of]";

MAILING ADDRESS OF SENDER:

PATENT NO. 6,911,425

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303

No. of additional copies



**Notice of Allowability**

C 17  
JUL 26 2005  
U.S. PATENT & TRADEMARK OFFICE

Application No.	Applicant(s)
09/812,485	KUMAGAI ET AL.
Examiner	Art Unit
Chih-Min Kam	1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to 7/1/04.
2.  The allowed claim(s) is/are 16-19.
3.  The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a)  All
  - b)  Some\*
  - c)  None
 of the:
  1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
  - (a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1)  hereto or 2)  to Paper No./Mail Date 5/5/03.
  - (b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

1. <input type="checkbox"/> Notice of References Cited (PTO-892)	5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	6. <input checked="" type="checkbox"/> Interview Summary (PTO-413), Paper No./Mail Date <u>2004-1116</u> .
3. <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date <u>10/6/04</u>	7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment
4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance
	9. <input type="checkbox"/> Other _____.

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Karl Boziceric on November 16, 2004.

**Examiner's Amendments to the Claims:**

Claims 16-19 have been amended as follows:

16. (Currently Amended) A toothpaste, comprising:

a paste carrier; and

[a therapeutically effective amount of] a peptide chosen from ERGDNDISPFSGDGQ (SEQ ID NO:47) and TDLQERGDNDISPFSGDGQPKD (SEQ ID NO:49).

17. (Currently Amended) A mouthwash, comprising:

an aqueous flavored solution; and

[a therapeutically effective amount of] a peptide chosen from ERGDNDISPFSGDGQ (SEQ ID NO:47) and TDLQERGDNDISPFSGDGQPKD (SEQ ID NO:49).

18. (Currently Amended) A patch for application on gum tissue of a patient;

comprising: a patch carrier component; and

[a therapeutically effective amount of] a peptide chosen from ERGDNDISPFSGDGQ (SEQ ID NO:47) and TDLQERGDNDISPFSGDGQPKD (SEQ ID NO:49).

19. (Currently Amended) A dental floss comprising:

a floss carrier component; and

[a therapeutically effective amount of] a peptide chosen from ERGDNDISPFSGDGQ (SEQ ID NO:47) and TDLQERGDNDISPFSGDGQPKD (SEQ ID NO:49).

Art Unit: 1653

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8:00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached at 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chih-Min Kam, Ph. D. CMK  
Patent Examiner

CMK  
November 16, 2004



JON WEBER  
SUPERVISORY PATENT EXAMINER

**Interview Summary**

Application No.	Applicant(s)	
09/812,485	KUMAGAI ET AL.	
Examiner	Art Unit	
Chih-Min Kam	1653	

All participants (applicant, applicant's representative, PTO personnel):

(1) Chih-Min Kam. (3) \_\_\_\_\_.

(2) Karl Boziceric. (4) \_\_\_\_\_.

Date of Interview: 16 November 2004.

Type: a) Telephonic b) Video Conference  
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 16-19.

Identification of prior art discussed: \_\_\_\_\_.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: To amend claims 16-19 as indicated in the Examiner's Amendment.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

*CBK* AS 2 - 2005  
\_\_\_\_\_  
Examiner's signature, if required